Medtronic Expands Option for the CD Horizon® Solera(TM) System
MEMPHIS, TENN., - July 19, 2012 - Medtronic, Inc. (NYSE: MDT) today announced the initiation of the global launch of the CD HORIZON® SOLERA(TM) 5.5/6.0 System. This product launch is part of the CD HORIZON® family of fixation devices, designed to provide spinal stabilization and correction as an adjunct to fusion in patients suffering from painful and function-limiting disorders of the middle and lower back.
The CD HORIZON® SOLERA(TM) 5.5/6.0 System extends the capability of the CD HORIZON® SOLERA(TM) 4.75 System launched in 2011 and offers the surgeon the ability to customize the spinal construct to match the patients' needs by offering an implant system that accommodates two diameter spinal rods and an array of materials. Spinal construct customization allows for targeted applications ranging from high demand spinal surgical cases such as adult deformity, adolescent idiopathic scoliosis (AIS) and tumor/trauma cases to lower demand degenerative spinal conditions.
"By leveraging the full CD HORIZON® SOLERA(TM) System, spinal pathologies and patient factors can be treated with less inventory than the typical spinal implant system," says Doug King, Senior Vice President, President of Medtronic Spinal. "This innovation now accommodates multiple spinal rod dimensions and materials with two implant platforms which provide an additional variety of options to meet unique patient needs."
The CD HORIZON® SOLERA(TM) System is designed to work with the POWEREASE(TM) System, an innovative system of powered instruments designed for drilling, tapping, and driving screws and working end attachments during spinal surgery, including open and minimally invasive procedures.
About the CD HORIZON® SOLERA(TM) Spinal System
Medtronic's CD HORIZON® SOLERA(TM) Spinal System is Medtronic's latest innovative spinal fusion system and is cleared to treat patients with degenerative disc disease, spinal stenosis, fracture, dislocation, failed previous fusions, tumors and adolescent idiopathic scoliosis (AIS). With more than twenty-five years clinical experience and 500,000 patients treated with the CD HORIZON® product line, the CD HORIZON® SOLERA(TM) Spinal System offers the combination of lower profile pedicle screw implants and performance. Notably, the system accommodates multiple rod material options and gives surgeons and hospitals an array of choices to treat a diverse set of spinal conditions.
Risks associated with such a system include loosening, disassembly, bending, and/or breakage of components, fracture, microfracture, resorption, damage, or penetration of any spinal bone. Selection of the proper size, shape, and design of the implant for each patient is crucial to its safe use. A successful result is not always achieved in every surgical case. The safety and effectiveness of this device has not been established for use as part of a growing rod construct when used in pediatric cases, and is only intended to be used when definitive fusion is being performed at all instrumented levels.
About the Spinal Business at Medtronic
The Spinal business, based in Memphis, Tenn., is the global leader in today's spine market and is committed to advancing the treatment of spinal conditions. The Spinal business collaborates with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for orthopaedic and spinal conditions. The company is committed to developing affordable, minimally invasive procedures that provide lifestyle friendly surgical therapies. More information about the company and its spinal treatments can be found at www.medtronicspinal.com and its patient-education Web sites, www.back.com, www.iscoliosis.com, www.maturespine.com and www.necksurgery.com.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.